International Review of Ophthalmology ›› 2023, Vol. 47 ›› Issue (3): 223-227.doi: 10.3760/ cma.j.issn.1673-5803.2023.03.005

Previous Articles     Next Articles

Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

Zhu Jian, Chen Yixun, Zhu Rongrong   

  1. Department of Ophthalmology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001,China
  • Received:2022-12-08 Online:2023-06-22 Published:2023-06-29
  • Contact: Zhu Rongrong, Email: zrreye@126.com
  • Supported by:
    Nantong Science and Technology Plan Project (MSZ20180)

Abstract: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is currently the first-line treatment for age-related macular degeneration (AMD). The commonly used anti-VEGF drugs are Avastin, Ranibizumab, Aflibercept and Brolucizumab. For patients with AMD, the half-life, time to peak and drug concentration in atrial fluid, vitreous humour and serum are different between drug. In addition, different ophthalmic procedures such as cataract surgery, vitectomy and silicone oil filling can cause pharmacokinetic changes. It is recommended to use anti-VEGF drugs with long half-live and lasting efficacy in clinical treatment.(Int Rev Ophthalmol, 2023, 47: 223-227)

Key words: age-related macular degeneration, intravitreal injections, anti-vascular endothelial growth factor drug, pharmacokinetics